PRZOOM - /newswire/ -
San Jose, CA, United States, 2007/05/29 - Bioactivation of drug candidates resulting in chemically reactive, electrophilic metabolites have always presented a major challenge to pharmaceutical companies.
Moreover, the measurement of these metabolites has been hampered by the lack of an effective quantitative method. QA-GSH is a novel new tool for the detection of reactive metabolites.
QA-GSH is a novel quaternary ammonium glutathione analogue conjugating agent described by Soglia, et al.1 Developed by Pfizer, this compound can provide semiquantitative assessment of the bioactivation potential in vitro. for semiquantitative LC-MS/MS detection of reactive metabolite. The methodology is well suited for use in early drug discovery high throughput screening paradigms.
QA-GSH is available from AnaSpec, a leading provider of integrated proteomics solutions.
About AnaSpec, Inc.
AnaSpec, Inc. (anaspec.com) is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and combinatorial chemistry. Established in 1993, AnaSpec's ISO9001:2000 certified headquarters and manufacturing facilities are located in San Jose, CA.
1. Soglia, J.R.; G. Contillo, L.G.; Kalgutkar, A.S.; Zhao, S.; Hop, C.E.C.A.; Boyd, J.G.; Cole, M.J. A semiquantitative method for the determination of reactive metabolite conjugate levels in vitro utilizing liquid chromatography-tandem mass spectrometry and novel quaternary ammonium glutathione analogues, Chem. Res. Toxicol. 2006, 19, 480-490